Skip to main content
. Author manuscript; available in PMC: 2022 Jun 22.
Published in final edited form as: J Am Acad Dermatol. 2014 Jun 20;71(3):468–474. doi: 10.1016/j.jaad.2014.04.053

Fig 1.

Fig 1.

Response of a patient with bullous pemphigoid (BP) after 6 omalizumab injections as monotherapy. A, Involvement of the back of a steroid-refractory patient with BP before omalizumab treatment. B, Four months after beginning omalizumab as monotherapy, the inflammatory plaques have largely resolved, leaving postinflammatory hyperpigmentation and a small number of erosions and mild, transient erythema. The patient cleared completely after a second cycle of omalizumab treatment.